Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche to fight Amgen injunction

Roche to fight Amgen injunction

10th April 2008

A preliminary court injunction preventing the sale of the anaemia drug Mircera is to be appealed by its manufacturer, it has emerged.

Reuters reports that Roche has this week filed an appeal against the decision for US sales of Mircera to be prohibited stating that the product does not infringe on the patents on one of its rivals.

It had previously been asserted by Amgen last year that Roche had breached patent laws relating to two of its own anaemia drugs, Epogen and Aranesp, which was upheld by the court in Amgen’s favour.

However, despite suggestions by judge William Young that Amgen could license the patents on Epogen and Aranesp in exchange for a licensing fee, a statement from the firm suggests that a permanent ban is the desired outcome.

“We look forward to arguing the case for protection of intellectual property against a proven infringer in the appellate court,” the news agency reports Amgen said in a statement.

FDA News reported recently that phase II trials for Roche’s investigational cholesterol inhibitor R1658 had been a success.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.